Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
New York State Psychiatric Institute
Modality
UNKNOWN
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05690503CT.gov Glutamatergic Modulation as a Treatment for Depressive Symptoms Among Patients With Post-acute Sequelae of COVID (PASC): A Pilot Trial | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Depressive Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| ci-581a (this asset) | New York State Psychiatric Institute | P2 | CCC · 53 |
| Brexpiprazole | Dr. Albert Kar-Kin Chung | P4 | A |
| Jnj-54135419 | Chinese PLA General Hospital | P4 | BBB |
| Saredutant | Sanofi | P3 | BBB |
| Lithium, Elemental | Rakitzi, Stavroula | P4 | BBB |
| Escitalopram | Poznan University of Medical Sciences | P4 | BBB |
| VENLOR | Janssen Research & Development, LLC | P4 | BBB |
| Fluoxetine | University of Oxford | P4 | BBB |
| Paroxetine | Brigham and Women's Hospital | P4 | BBB |
+42 more in the Depressive Disorder cohort
Other indications for ci-581a
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Long COVID-19 | — | P2 | CCC · 53 |
| Cognitive Disorder | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. ci-581a in Depressive Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ci-581a-depressive-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →